The effects of different regimens of 40 mg aspirin on platelet thromboxane A2 synthesis and vascular prostacyclin synthesis were determined in patients who were undergoing elective surgery for removal of varicose veins. Aspirin 40 mg taken at intervals of 48 hours consistently reduced platelet thromboxane A2 synthesis to a level at which it failed to support platelet aggregation and the associated release reaction. This effect lasted for at least 36 hours. In contrast, aspirin 40 mg every 72 hours did not have the same consistent effect. Both dose regimens led to a reduction in vascular prostacyclin synthesis 12 hours after the last dose, but 36 or 72 hours after the last dose prostacyclin synthesis was not reduced; thus the inhibition of prostacyclin synthesis was short lived.
Introduction
Blood platelets and blood-vessel walls contain cyclo-oxygenase enzymes that convert arachidonic acid into prostaglandins and thromboxanes. The principal end product of the reaction sequence in platelets is thromboxane A2,' while that in blood vessels is prostacyclin.2 3 Since thromboxane A2 is able to induce platelets to aggregate,' to undergo the platelet release reaction. and is a vasoconstrictor,4 it is considered to be prothrombotic. In contrast, prostacyclin is a potent inhibitor of platelet behaviour,2 3 6 is a vasodilator,7 8 and so may be antithrombotic.
The cyclo-oxygenase present in platelets and in vessel walls are both inhibited by aspirin, which thus prevents the synthesis of the potentially thrombotic thromboxane A2 and the potentially antithrombotic prostacyclin. Studies in animals and in-vitro studies on human tissues, however, have suggested that the enzymes in platelets and vascular tissue may be differentially sensitive to acetylation by aspirin,9-12 so that a regimen of aspirin might exist that inhibits synthesis of thromboxane A2 while sparing the synthesis of prostacyclin in veins and arteries. Such studies also suggested that the effect of aspirin on vascular tissue may be of shorter duration than the effect on platelets"3-15; veins and arteries, unlike platelets, are able to resynthesise new enzyme. Studies carried out after platelets and venous tissue had been removed from volunteers who had ingested a single dose of aspirin confirmed the differential sensitivity of platelets and vascular tissue to aspirin and suggested that the dose of choice might be 40 mg.16 Such studies did not, however, indicate a different duration of effect of aspirin on the different tissues.
The purpose of the present study was to determine the effects on platelet thromboxane A2 and vascular prostacyclin synthesis of different regimens of 40 mg aspirin in an attempt to identify a schedule that would alter the balance between synthesis of thromboxane A2 and prostacyclin in a potentially favourable direction. Vessel studies-Vessels were obtained from all the patients at operation and were handled as described previously.'6 Their capacity for synthesis of prostacyclin was determined by incubating two 6 mm discs of tissue in plasma that contained sodium arachidonate (final concentration 1 mmol/l (32-7 mg/100 ml)) and measuring the amount of prostacyclin that was produced. The amounts of prostacyclin produced by vessel segments from the patients who took no aspirin (group 1) ranged from 17 to 13-7 ng; thus the range was similar to that obtained previously. '6 The mean amount of prostacyclin generated 12 hours after three doses of 40 mg aspirin had been taken at intervals of 24 hours (group 2) was less than that generated in the controls (group 1). This reduction in the capacity of the venous tissue to produce prostacyclin did not, however, achieve significance at the 5% level.
Patients and methods
Twelve hours after three doses of 40 mg aspirin had been taken at intervals of 48 hours (group 3a) significantly less (p < 0 01) prostacyclin was produced than in the controls. Thirty-six hours after three doses of 40 mg aspirin at intervals of 48 hours (group 3b) rather more prostacyclin was produced than in the controls. The mean amount of prostacyclin produced 36 hours after the last dose was significantly higher than that produced 12 hours after the last dose (p < 0 001).
Twelve hours after three doses of 40 mg aspirin had been taken at intervals of 72 hours (group 4a) the mean amount of prostacyclin produced was lower than that in the controls and at 72 hours after the last dose the mean amount produced was higher than in the controls. Neither of these differences was significant at the 5% level, but the means at 12 and 72 hours were significantly different from each other (p < 0 02).
PLATELET STUDIES Before ingestion of aspirin the amounts of malondialdehyde generated by platelets from 32 of the 35 patients studied ranged from 5-8 to 14-7 nmol/109 platelets. In each case the amount ofthromboxane produced was sufficient to induce the formation of large platelet aggregates and an extensive release reaction occurred. Platelets from the three other patients produced less than 1 nmol malondialdehyde, which was not sufficient to induce aggregation or a release reaction. The possibility that these patients had taken aspirin or other nonsteroidal anti-inflammatory agents before the study cannot be excluded.
In the five patients whose platelets were studied before and then 12 hours after three doses of 40 mg aspirin were taken at intervals of 48 hours (group 3a) platelet aggregation and a release reaction did not occur and the amount of malondialdehyde produced was less than 0 7 nmol/109 platelets. In the seven patients whose platelets were studied 36 hours after the same dose regimen (group 3b) platelet aggregation and a release reaction did not occur and the amount of malondialdehyde produced was less than 1-3 nmol/109 platelets (figs 1 and 2).
In nine of the 11 patients whose platelets were studied before and then 12 hours after three doses of 40 mg aspirin were taken at intervals of 72 hours (group 4a) and in eight of the 12 patients whose platelets were studied before and then 72 hours after the same dose regimen (group 4b) platelet aggregation and a release reaction did not occur and the amount of malondialdehyde produced was less than 16 nmol/109 platelets. In the six other patients in group 4 greater amounts of malondialdehyde were produced and aggregation and a release reaction still occurred (figs 3 and 4). production.'9 In the present study we have shown that this cumulative effect is also evident after 40 mg aspirin is taken at intervals of 48 hours. Platelets from all 12 patients studied after completing the dose regimen failed to produce enough thromboxane A2 to support platelet aggregation and the associated release reaction. Platelets from nine of 11 patients studied 12 hours after completing a dosage schedule of 40 mg aspirin at intervals of 72 hours produced little thromboxane A2, but 72 hours after completion of the regimen thromboxane A2 produced in four of 12 patients was sufficient to allow aggregation and the release reaction to proceed.
The present studies also show that repeated doses of 40 mg aspirin have a cumulative effect on venous prostacyclin production: production was decreased 12 hours after the last dose of aspirin whether the aspirin had been taken at intervals of 24, 48, or 72 hours. The effects of these regimens, however, were not long lasting: within 36 or 72 hours venous prostacyclin production was restored and, indeed, appeared to be greater than that in vascular tissue from patients who had not taken any aspirin. The short duration of the effect of multiple 40 
Introduction
The introduction of the radioimmunoassay of adrenocorticotrophic hormone (ACTH) has allowed circulating concentrations of plasma ACTH to be measured easily both in normal subjects and in patients with Cushing's disease.'-4 The belief that there is an overlap between the range of morning ACTH concentrations found in patients with Cushing's disease and that found in normal subjects has led to some confusion about the diagnosis of Cushing's disease, particularly for those who are not endocrinologists. We feel that the diagnostic difficulties due to this apparent overlap have arisen because of a failure to define accurately the timing of the normal range in normal subjects. We also believe that the traditional "9 am" measurement of ACTH does distinguish patients with Cushing's disease from normal subjects if properly timed.
Patients and methods
A total of 58 normal control subjects were studied. The group comprised laboratory staff not receiving hospital treatment and inpatients who had no endocrine disorder and were not under stress: these patients were either women admitted for laparoscopic sterilisation or patients of either sex admitted to the ear, nose, and throat ward for aural toilet. None of the control group were taking any medication. $Blood glucose falling below 2-2 mmol/l (39 mg/100 ml).
§Normal range 220-1050 nmol/24 h.
